Skip to main content
. 2016 Aug 2;2016:8123138. doi: 10.1155/2016/8123138

Figure 1.

Figure 1

Plasma α-defensins (HNP1–3) levels of IgAN patients and healthy controls. The line was mean levels of α-defensins for 169 IgAN patients (78.42 ng/mL) defined as the cut-off for dividing patients into two groups with high (above 78.42 ng/mL) and low (below 78.42 ng/mL) α-defensins levels.